Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Inhaled Corticosteroids
100%
Long-term Response
100%
Leukotriene Modifiers
100%
Pediatric Asthma
100%
Fluticasone Propionate
100%
Montelukast
80%
Patient Benefit
60%
Asthma Control
60%
Inhaled Corticosteroid Therapy
60%
PC20
60%
Exhaled Nitric Oxide
60%
Nitric Oxide Level
60%
Controller
40%
Treatment Response
40%
Asthma
40%
Phenotypic Characteristics
40%
Moderate to Severe
20%
Multivariate Analysis
20%
Predictive Value
20%
Peak Expiratory Flow
20%
Once-daily
20%
Twice Daily
20%
Forced Expiratory Volume in 1 Second (FEV1)
20%
Treatment Duration
20%
Aeroallergens
20%
Persistent Asthma
20%
Leukotriene Receptor Antagonist
20%
Pre-bronchodilator FEV1
20%
Treating children
20%
Asthma Exacerbation
20%
Differential Treatment
20%
Test Response
20%
Medicine and Dentistry
Pediatrics
100%
Asthma
100%
Leukotriene
100%
Fluticasone
62%
Montelukast
50%
Nitric Oxide
37%
Treatment Response
25%
Multivariate Analysis
12%
Peak Expiratory Flow
12%
Aeroallergen
12%
Prick Test
12%
Corticosteroid Therapy
12%
Leukotriene Receptor Blocking Agent
12%
Moderate Persistent Asthma
12%
Asthma Exacerbation
12%
Biochemistry, Genetics and Molecular Biology
Leukotriene
100%
Fluticasone
100%
Montelukast
80%
Nitric Oxide
60%
Multivariate Analysis
20%
Receptor Antagonist
20%
Peak Expiratory Flow
20%
Immunology and Microbiology
Asthma
100%
Leukotriene
100%
Fluticasone
62%
Montelukast
50%
Exhaled Nitric Oxide
37%
Leukotriene Antagonist
12%
Peak Expiratory Flow
12%
Moderate Persistent Asthma
12%
Asthma Exacerbation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Fluticasone
55%
Montelukast
44%
Nitric Oxide
33%
Leukotriene Receptor Blocking Agent
11%